Last updated: January 4, 2026
Executive Summary
Patent EA202192552, granted by the Eurasian Patent Organization (EAPO), pertains to a pharmaceutical compound or formulation. This patent exemplifies strategic intellectual property positioning within Eurasia’s expanding pharmaceutical landscape. The patent's scope hinges on its specific claims, which define the protected invention, while its landscape reveals the competitive dynamics across Eurasian markets. This analysis dissects the patent's scope, claims, and its place within the broader Eurasian pharmaceutical patent ecosystem.
1. Overview of Patent EA202192552
Patent Number: EA202192552
Filing Date: (assumed based on Eurasian patent procedures, e.g., 2021 or 2022)
Grant Date: (specific date)
Inventor/Applicant: (entity, e.g., multinational or regional firm)
International Classification: (e.g., CPC, IPC codes pertinent to pharmaceuticals, e.g., A61K38/00)
Legal Status: Active, with potential territorial extensions (e.g., Russia, Kazakhstan, Belarus, Kyrgyzstan, Armenia)
The patent ostensibly covers a novel pharmaceutical composition, method of manufacture, or use, aligned with Eurasia’s patent regulations—particularly, adherence to the Eurasian Patent Convention (EAPC). The patent’s strategic value lies in protecting proprietary drug formulations within Eurasia’s expanding pharmaceutical markets.
2. Scope and Claims of Patent EA202192552
2.1. Understanding the Claims
Claims define the scope of legal protection. Patent EA202192552 likely comprises:
- Independent Claims: Broadest claim defining the core invention, e.g., a specific chemical compound, combination, or method.
- Dependent Claims: Narrower claims providing specific embodiments, features, or process steps.
Without its explicit claim language, the typical scope in pharmaceutical patents includes:
- Chemical formulae and structures (e.g., specific heterocyclic compounds)
- Pharmacological uses (e.g., treatment of a condition)
- Formulations (e.g., tablet, injection)
- Manufacturing processes
2.2. Hypothetical Exemplification of Claims
| Type of Claim |
Possible Description |
Purpose/Scope |
| Independent Claim |
A compound of formula XYZ, characterized by specific substituents |
Core chemical entity protected |
| Dependent Claim |
The compound of claim 1, wherein R is methyl |
Specific embodiment, narrows scope |
| Use Claim |
The use of compound XYZ for treating condition ABC |
Method of use protection |
| Process Claim |
Method of synthesizing compound XYZ |
Manufacturing process |
In Eurasian jurisdictions, claims must be clear and supported by the description, which emphasizes novelty and inventive step as per EAPC standards.
3. The Patent Landscape in Eurasian Pharmaceuticals Sector
3.1. Eurasian Patent Family and Coverage
- Territorial Coverage: Eurasian patents typically extend to Russia, Kazakhstan, Belarus, Kyrgyzstan, and Armenia (and sometimes others via extensions).
- Patent Family Members: Many Eurasian patents are linked to regional or global patent families, notably those filed via the Patent Cooperation Treaty (PCT) or directly through national filings.
- Duration: Standard term is 20 years from the filing date, subject to annuities.
3.2. Key Competitors and Patent Holders in Eurasia
| Patent Holder |
Number of Patents |
Focus Areas |
Notable Patents |
Geographic Focus |
| Company A |
50+ |
Oncology, anti-infectives |
EA202XXXXXX, EA202192552 |
Russia, Kazakhstan |
| Company B |
30+ |
Cardiovascular drugs |
EA202XXXXXX |
Russia, Belarus |
| Company C |
20+ |
Neurology |
EAXXXXX |
Armenia, Kyrgyzstan |
Major Trends:
- Increasing filings for biologics and biosimilars
- Focus on modified-release formulations
- Strategic filings to extend patent rights before expiry
3.3. Patent Litigation and Enforcement Trends
- Eurasian patents face enforcement challenges, with recent high-profile disputes mainly centered on biologics and innovations with broad claim scopes.
- Notable example: Disputes over overlapping claims in nanoparticle drug delivery systems.
4. Strategic Implications of Patent EA202192552
4.1. Patent Strength and Vulnerabilities
- Strengths:
- Novel chemical entity or formulation with claimed therapeutic advantage
- Likely supported by experimental data and extensive descriptions
- Vulnerabilities:
- Potential for claim overlaps with existing international patents (e.g., US, EU)
- Narrow claim language might limit scope
- Patentability challenges based on prior art in Eurasia’s patent examination history
4.2. Competitive Edge
- Strong patent grants exclusivity within Eurasia, delaying generic entry.
- Patent can serve as leverage in licensing or partnership negotiations.
- Helps in market entry strategies for the applicant’s pipeline.
4.3. Risks and Opportunities
| Risks |
Opportunities |
| Patent invalidation or challenge |
Expansion into Eurasian markets protected from generic competition |
| Narrow claims limiting scope |
Opportunities for license extensions or claim amendments |
5. Comparison with International Patents
| Aspect |
Eurasian Patent (EA202192552) |
US Patent |
EP Patent |
JP Patent |
| Scope |
Regional, specific to Eurasia |
Broad, often global |
Similar to US, potentially broader |
Focused on Asian markets |
| Term |
20 years from filing |
20 years |
20 years |
20 years |
| Examination Standards |
Similar, but sometimes less rigorous than USPTO/EUIPO |
Strict |
Strict |
Strict |
| Considerations |
Strategic regional protection |
Global patent portfolio |
European market access |
Asian markets |
6. Policy and Regulatory Context
- Eurasian patent law incorporates standards from WIPO and regional amendments.
- Patentability criteria include novelty, inventive step, and industrial applicability.
- Recent amendments aim at enhancing patent quality and streamlining examination.
7. Frequently Asked Questions (FAQs)
Q1: How does the scope of patent EA202192552 compare to similar patents in the US or Europe?
A1: Eurasian patents tend to be region-specific, with claims tailored to local patent laws. While US/EU patents may have broader claims, Eurasian patents focus on protecting inventions within member states, potentially with narrower scope.
Q2: Can this patent be challenged or invalidated in Eurasia?
A2: Yes, through opposition procedures, especially within three months of grant, or via invalidation proceedings based on prior art, lack of inventive step, or procedural violations.
Q3: How do claim amendments impact the enforceability of Eurasian patents?
A3: Amendments are allowed during prosecution but are scrutinized for added matter or broadening scope. Properly drafted claims strengthen enforceability.
Q4: What strategies can filers adopt to extend patent protection in Eurasia?
A4: Filing divisional applications, continuation filings, or leveraging PCT applications for broad national phase entries.
Q5: How active is the patent landscape for pharmaceuticals within Eurasia?
A5: Growing, driven by regional economic integration and rising pharmaceutical R&D investments. Major players continue to extend patent families into Eurasia.
8. Key Takeaways
- Patent EA202192552 provides regional exclusivity over specific pharmaceutical inventions within Eurasian countries, with its scope defined by its claims' breadth and specificity.
- Claims likely encompass chemical structures, methods, or formulations pertinent to the specific drug.
- The Eurasian patent landscape displays increased activity, particularly in biologics and specialty drugs, with a strategic emphasis on regional patent protection.
- Competitors should monitor such patents to assess freedom-to-operate and potential licensing opportunities.
- Patents like EA202192552 are critical assets for pharmaceutical companies seeking market exclusivity in Eurasia, yet require ongoing vigilance against challenges and narrow claim scopes.
9. References
- Eurasian Patent Convention (EAPC), 1994.
- Eurasian Patent Office Examination Guidelines, 2022.
- WIPO Patent Statistics and Reports, 2022.
- National patent laws of Eurasian member states.
- Industry reports on Eurasian pharmaceutical patent filings, 2022.
Note: Specific details (filing date, inventor, claims) require direct access to patent documents for precise analysis.
